
Opinion|Videos|January 20, 2025
Future Perspectives on the Relapsed/Refractory Follicular Lymphoma Treatment Landscape
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs are being addressed through ongoing trials while reflecting on proud accomplishments in the field and expressing enthusiasm for developments in the coming year.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some remaining unmet needs in treating relapsed/refractory follicular lymphoma?
- What trials of interest are ongoing? What are future considerations?
- What accomplishments in this space are you most proud of?
- What are you most excited about in the coming year?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
5



















